TLR7 and cancer: One example of this is R848, a dual TLR7 and TLR8 synthetic agonist previously shown to promote an anti-cancer and anti-bacterial immune response (Bhagchandani et al., 2021), suggesting that it might also have relevance in wound healing settings as well.